Author

Marco Missanga

Observed names: M Missanga, Marco Misanga, Marco Missanga Amani Kway

Institution: National Institute for Medical Research

Observed institution: National Institute for Medical Research

ORCID: 0000-0003-0001-2303

Observed ORCID: 0000-0003-0001-2303

OpenAlex ID: A5113866760

Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial

2015 · Patricia. J. Munseri, Arne Kroidl, et al. · PLoS ONE · 43

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

2018 · Edna O. Viegas, Arne Kroidl, et al. · PLoS ONE · 28

PDF

Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost

2017 · Julie A Ake, Alexandra Schuetz, et al. · The Journal of Infectious Diseases · 28

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial

2016 · Agricola Joachim, Asli Bauer, et al. · PLoS ONE · 20

PDF

Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen

2017 · Asli Bauer, Lilli Podola, et al. · Journal of Virology · 9

Examining oral pre-exposure prophylaxis (PrEP) literacy among participants in an HIV vaccine trial preparedness cohort study

2022 · Rujeko Samanthia Chimukuche, Rachel Kawuma, et al. · BMC Health Services Research · 8

PDF

Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence

2019 · Yuka Nadai, Kathrin Held, et al. · Frontiers in Immunology · 8

PDF

Standard of care in advanced HIV disease: review of HIV treatment guidelines in sub-Saharan African countries—an extension study of eight countries

2025 · Thomas C. Scheier, Tafese Beyene Tufa, et al. · AIDS Research and Therapy · 3

High prevalence of ST-elevation, early repolarization, and left ventricular hypertrophy during the eligibility assessment for an HIV vaccine trial in young, healthy Tanzanians

2017 · Philipp Mann, Patricia Munseri, et al. · Clinical Trials and Regulatory Science in Cardiology · 3

PDF

Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study

2026 · Rachel Kawuma, Sarah Nakamanya, et al. · Trials · 1

Evaluation of Performance Characteristics of the StandardTM Q IgM/IgG and the Wantai SARS-CoV-2 Ab Rapid Tests in Tanzania

2024 · Lwitiho Sudi, George P. Judicate, et al. · East Africa Science · 1

Intradermal Electroporation of HIV-DNA Vaccine Followed by HIV-MVA Boost with or Without Addition of GLA Adjuvanted gp140

2016 · Edna Viegas, Marco Missanga, et al. · UCL Discovery (University College London) · 1

Safety, Tolerability, and Immunogenicity of the TANCoV-1.3.20 SARS-CoV-2 Vaccine Among Healthy Participants in Tanzania: Protocol for a Multisite, Phase 1/2a, Double-Blinded Randomized Controlled Trial

2026 · George Peter Judicate, Marco Missanga, et al. · JMIR Research Protocols

Env-specific IgG Responses Induced by Identical and None-identical Immunogen Prime-boost Vaccination Strategies Target Different Antigenic Regions

2016 · Yuka Nadai, Mohamed I. M. Ahmed, et al. · UCL Discovery (University College London)

Phase 1 Trial of the Safety and Immunogenicity of PENNVAX ® -G DNA Prime Administered by Biojector ® 2000 or CELLECTRA ® EP Device with MVA-CMDR Boost

2014 · Julie Ake, Silvia Ratto-Kim, et al. · AIDS Research and Human Retroviruses

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen

2012 · L Podola, A Bauer, et al. · Retrovirology

PDF

High prevalence of ECG variations and abnormalities in young and healthy TaMoVac 01 HIV vaccine trial volunteers from Tanzania

2012 · PJ Mann, P Munseri, et al. · Retrovirology

PDF

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime

2012 · A Bauer, L Podola, et al. · Retrovirology

PDF

Works count: 18

Citation count: 153

H-index: 7

I10-index: 4